Macrogenics Q2 EPS $(0.89) Misses $(0.59) Estimate, Sales $10.80M Miss $21.24M Estimate
Portfolio Pulse from Benzinga Newsdesk
Macrogenics (NASDAQ:MGNX) reported Q2 earnings per share (EPS) of $(0.89), missing the analyst estimate of $(0.59) by 50.85%. Sales were $10.80M, missing the $21.24M estimate by 49.16%. This represents a 196.74% decrease in EPS and a 17.81% decrease in sales compared to the same period last year.
August 06, 2024 | 8:38 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Macrogenics reported Q2 EPS of $(0.89), missing estimates by 50.85%, and sales of $10.80M, missing estimates by 49.16%. This significant miss in both earnings and sales is likely to negatively impact the stock price in the short term.
The significant miss in both EPS and sales compared to analyst estimates, along with a substantial year-over-year decrease in both metrics, suggests a negative short-term impact on the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100